Endocrine Abstracts

Aim: This study aimed to evaluate the changing needs, improvement suggestions and user satisfaction with hybrid closed loop (HCL) insulin pump therapy, focusing on its impact on daily life and diabetes management in a real-world setting.

Methods: A structured questionnaire was developed using Microsoft Forms and distributed initially via Digibete platform. Families were approached in outpatient clinic (OPD) and given the option to participate in this anonymised feedback. The survey collected information on the duration of diabetes, length of HCL pump use, and the perceived impact on glycaemic control and quality of life, including anxiety related to diabetes care, hypoglycaemia, and sleep. Participants were also asked about the Diabetes updates they would like and were invited to provide free-text comments on suggestions for improvement.

Results: Of the 29 families approached in OPD, 27 completed the questionnaire. Ninety-six percent reported that the system met their expectations, while 4% felt it did so to some extent. Patients ranged in age from 6 to 16 years and had used HCL therapy for 5 to 18 months. Eighty-nine percent reported improved time-in-range for blood glucose levels, and all respondents mentioned improvements in glycaemic control during meals, exercise and overnight and recommend HCL to others. All participants reported reduced fear of hyperglycaemia, hypoglycaemia, and diabetic ketoacidosis. Seventy-eight percent felt safer using HCL and 63% reported reduced anxiety and improved sleep. Users reported that the system was beneficial when mealtime insulin was missed. Positive descriptive terms such as “game changer” and “magic wand” were used to describe their experience. Desired updates included guidance on pump failure, reinforcing the difference of managing parameters like hypoglycaemia to overcome previous habits, skin care, travel with pump and sick day management using HCL. Users suggested improvements included full automation, technical prompts to return to Auto Mode, wider infusion site options, and simplified mealtime adjustments without bolus.

Conclusion: This evaluation demonstrates high levels of user satisfaction with HCL insulin pump therapy, with significant perceived improvements in glycaemic control, safety, and quality of life. The findings also highlight evolving user needs with change in technology and areas for future technological development.